Skip to main content

Leukemia, lymphoma, and myeloma.

265 studies recruiting right now, most recently updated first.

Open the Phase 2 page · a list of only those studies

Triangle is made by Triangle Health, Inc.

Leukemia, lymphoma, and myeloma265 studies

Relapsed or Refractory Acute Myeloid LeukemiaPhase 1NCT07025564Papers

miRisten (miR-126 Inhibitor)

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

City of Hope Medical CenterOpen the brief

Advanced Myeloproliferative Neoplasms, MDS/MPN and High-Risk CMMLPhase 1/2NCT06523556

Axatilimab ± Azacitidine

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Uma BorateOpen the brief

NeoplasmsPhase 1NCT05836896Papers

MDC-CAR-BCMA001 (BCMA directed CAR T-cells)

Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

Technische Universität DresdenOpen the brief

Relapsed or Refractory Aggressive B-Cell LymphomaPhase 1/2NCT06536049

Epcoritamab + Ibrutinib

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Yazeed SawalhaOpen the brief

Clinical trials: Phase 1 and Phase 2, explained